The Function of Hepatocellular Uptake Transporters is Affected by Free Cholesterol

Abstract

BackgroundWe have previously shown that several transporters located in the basolateral membrane of human hepatocytes e.g. NTCP, OCT1, OATP1B1, and OATP1B3 interact with each other. These interactions are due in part to their co‐localization in detergent resistant membrane domains and impact both function and expression. Understanding how transporter interaction and altered membrane cholesterol content impact the function of these drug uptake transporters has implications regarding pharmacological studies, drug development, and drug‐drug interaction predictions.AimWe wanted to test how both the addition and removal of free cholesterol to and from the plasma membrane alters the function and localization of drug transporters.MethodsThe function of NTCP or OCT1 was measured using HEK293 Flp‐In cells stably expressing either transporter. We treated the cells with methyl‐b‐cyclodextrin (MCD) to remove cholesterol or with a cholesterol‐MCD complex to add cholesterol. Lipid rafts were isolated from HEK293 Flp‐In cells or frozen human liver samples by homogenization in 1% Triton X‐100 and sucrose gradient centrifugation. Gradient fractions were analyzed by western blotting using positive and negative lipid raft markers as well as transporter specific antibodies.ResultsTreatment with MCD stimulated uptake by NTCP while inhibiting uptake by OCT1. Subsequent treatment of the MCD treated cells with the cholesterol‐MCD complex restored function in part for both NTCP and OCT1. Removal and restoration of membrane free cholesterol also impacted the co‐localization of the transporters within the detergent resistant membrane domains. We confirmed the differential localization of transporters in detergent resistant membranes comparing samples of normal and fatty human livers.Summary and ConclusionBoth adding or removing cholesterol alters transport function in a transporter‐dependent way. Furthermore, the localization of transporters in lipid rafts is different in normal and in fatty human livers. These results suggest that drug disposition is affected by fatty liver disease and that some drugs may be cleared faster or slower in patients with increased free cholesterol in the liver, due to NAFLD or NASH.Support or Funding InformationR01GM077336 and P30GM118247